CP and CPG patients have an increased lymphoma risk, linked to specific biomarkers, highlighting the importance of increased clinical vigilance in their management.
Royeck et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: